HC Wainwright Predicts Geron’s Q1 Earnings (NASDAQ:GERN)

Geron Corporation (NASDAQ:GERN) – HC Wainwright issued their Q1 2026 earnings per share estimates for Geron in a report released on Wednesday, November 5th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will post earnings per share of ($0.04) for the quarter. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s Q2 2026 earnings at ($0.03) EPS.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%. The business had revenue of $47.23 million for the quarter, compared to the consensus estimate of $55.24 million.

GERN has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a report on Friday, October 31st. Needham & Company LLC cut their price objective on Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.64.

Geron Stock Performance

Shares of Geron stock opened at $1.07 on Friday. The stock has a market cap of $682.68 million, a price-to-earnings ratio of -8.23 and a beta of 0.57. Geron has a twelve month low of $1.04 and a twelve month high of $4.33. The company’s fifty day moving average is $1.29 and its 200 day moving average is $1.35. The company has a quick ratio of 6.79, a current ratio of 7.87 and a debt-to-equity ratio of 0.46.

Institutional Investors Weigh In On Geron

A number of large investors have recently bought and sold shares of the stock. RA Capital Management L.P. lifted its position in shares of Geron by 101.2% during the first quarter. RA Capital Management L.P. now owns 60,379,366 shares of the biopharmaceutical company’s stock valued at $96,003,000 after purchasing an additional 30,369,830 shares in the last quarter. Soleus Capital Management L.P. increased its stake in Geron by 572.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 16,140,000 shares of the biopharmaceutical company’s stock valued at $22,757,000 after buying an additional 13,740,000 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of Geron by 100.0% during the 1st quarter. Vestal Point Capital LP now owns 22,005,340 shares of the biopharmaceutical company’s stock worth $34,988,000 after buying an additional 11,005,340 shares in the last quarter. Aberdeen Group plc boosted its stake in shares of Geron by 89.2% in the 2nd quarter. Aberdeen Group plc now owns 6,985,932 shares of the biopharmaceutical company’s stock worth $9,850,000 after buying an additional 3,293,179 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Geron by 325.0% in the 1st quarter. Deutsche Bank AG now owns 3,794,565 shares of the biopharmaceutical company’s stock worth $6,033,000 after buying an additional 2,901,655 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.